Prostate cancer vaccines, including dendritic and peptide types, offer hope for improved treatments, but face hurdles in ...

Data from the ongoing Phase 2 of EO4010 demonstrate tumor target specific immune responses and objective tumor responses, including in liver mets, in patients with previously treated microsatellite ...

The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of tumorigenesis, the TIME ...

The phase 3 clinical trial of CAN-2409 in intermediate-to-high-risk, localized prostate cancer met its primary endpoint, by demonstrating statistically significant improvement in disease-free survival ...

Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) ...

*仅供医学专业人士阅读参考前两天奇点糕才提到，对免疫治疗维持“绝对防御”的卵巢癌，可以通过分泌白介素-4（IL-4）调控巨噬细胞，构建免疫抑制性微环境，如果要给这种行为定性一下，大概可以算是卵巢癌对免疫治疗不敏感的“内因”。既然有内因，相对就一定会有 ...

About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease advance or recur following treatment. Seeking a new treatment strategy ...

Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated ...

Candel Therapeutics is a clinical-stage biopharmaceutical company that specializes in developing biological immunotherapies aimed at helping patients fight cancer. The company’s leading product, ...

The human papillomavirus (HPV), a common sexually transmitted infection, accounts for 70% of all throat cancers, according to the National Cancer Institute.